



Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

August 7, 2024 at 4:05 PM EDT

TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) announces the following September 2024 investor events:

Investor Conference Presentations

- Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024
- 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday, September 5, 2024

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at <https://investor.regeneron.com/events-and-presentations>. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

Oncology Webcast Information

- European Society for Medical Oncology (ESMO) 2024 conference call and webcast at 14:30 CEST/8:30 AM EDT on Monday, September 16, 2024

Regeneron will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio. A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at <https://investor.regeneron.com/events-and-presentations>. To participate via telephone, please register in advance at this [link](#). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as *VelociSuite*[®], which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center[®] and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on [LinkedIn](#), [Instagram](#), [Facebook](#) or [X](#).

Contact Information:

Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com



Source: Regeneron Pharmaceuticals, Inc.